

## About Asceneuron

Asceneuron is an emerging biotech company excelling in the discovery and development of ground breaking therapeutics for neurodegenerative disorders with high unmet medical need such as orphan tauopathies, Alzheimer's and Parkinson's diseases.

Asceneuron was founded in 2012 through a spin-off of Merck Serono's Alzheimer's drug discovery portfolio and research group in Switzerland. Asceneuron pursues a semi-virtual operating model. Our unique biochemical assays, biomarker discovery activities and pharmacology models are pursued in-house, while we collaborate with leading contract research organizations for other activities such as medicinal chemistry.

Our pipeline is composed of innovative small-molecule therapeutics aiming for **disease modulation** of tauopathies and **cognitive impairment**. Due to their nature, our molecules readily enter the brain and are orally bioavailable, meaning that they are suitable for dosage as tablets. For each program, we implement a clinical biomarker, that is expected to demonstrate that the drug reaches the intended target in humans and will support dose selection for the seminal proof-of-concept trials in patients.



## Portfolio

Our lead product, an O-GlcNAcase inhibitor that in preclinical studies has been demonstrated to modulate tau pathology, is currently completing the critical regulatory studies to initiate human clinical testing. The O-GlcNAcase inhibitor is being developed for the orphan tauopathy Progressive Supranuclear Palsy (PSP).

DISCOVERY	DEVELOPMENT CANDIDATES	IND ENABLING	PHASE 1
<b>TAUOPATHIES</b>			
<b>O-GLCNACASE INHIBITORS</b>			
PSP*			
FTD*			
AD*			
<b>COGNITIVE DYSFUNCTION IN DEMENTIA</b>			
<b>M1 PAM</b>			
PDD*			AD: Alzheimer's disease
LBD*			LBD: Lewy Body dementia
AD*			FTD: Frontotemporal dementia
			PDD: Parkinson's disease dementia
			PSP: Progressive Supranuclear Palsy

## Financial highlights

- ★ **2012** Seed funding CHF 6 million (USD 6.4 million)
- ★ **2015** Series A financing: CHF 30 million (USD 31.6 million)

Our drug development is supported by prestigious grants from world renowned foundations such as Cure PSP, the Alzheimer's Drug Discovery Foundation (ADDF) as well as The Michael J Fox Foundation.



## Management Team

**Dirk Beher** Ph.D.

Chief Executive Officer

**Christoph Wiessner** Ph.D.

Chief Operating Officer

**J. Michael Ryan** M.D.

Chief Medical Officer

**Anna Quattropani** Ph.D.

Head of Medicinal Chemistry

**Bruno Permanne** Ph.D.

Head of Biology

## Board of Directors

**Hans Schikan**

Chairperson, Director

**Dirk Beher**

Director, CEO Asceneuron

**Henriette Richter**

Director, Sofinnova Partners

**Hakan Goker**

Director, Merck Ventures

**Deborah Harland**

Director, SR One

**Jeanne Bolger**

Director, Johnson & Johnson Innovation -JJDC

**Vanessa Malier**

Director, Kurma Partners

**Professor Raymond Hill**

Independent Director

**Franz F. Hefti**

Special Advisor to the Board

## Investors

### Merck Ventures

